Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears

[cafead]

via What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer (NSCLC) could get clearer thanks to a first-in-class overall survival win from Merck & Co.’s Keytruda.

article source